ZLN005 Alleviates the Dopaminergic Degeneration via PGC-1α-Mediated Mitochondrial Homeostasis in Parkinson’s Disease

🎖️ Top 10% JournalDec 16, 2025Molecular neurobiology

ZLN005 may reduce dopamine cell loss by supporting energy control in Parkinson's disease

AI simplified

Longevity & Aging on OpenScience ↗PubMed ↗DOI ↗

Abstract

ZLN005 significantly reduced MPP/MPTP-induced neurotoxicity and improved motor deficits in a sub-acute mouse model of Parkinson's disease.

Mitochondrial dysfunction is associated with early features of Parkinson's disease, linked to energy regulation imbalances.
The synthetic PGC-1α activator ZLN005 may enhance mitochondrial performance and provide neuroprotection.
ZLN005 maintained the expression of key markers related to mitochondrial biogenesis and regulation.
Increased levels of proteins that enhance PGC-1α transcription, including SIRT1, were observed following ZLN005 treatment.
Mitochondrial integrity improved and oxidative stress reduced, as confirmed by imaging and flow cytometry.

AI simplified

Parkinson's disease (PD) is a neurodegenerative condition marked by significant motor impairments, resulting from extensive loss of dopaminergic neurons and abnormal protein aggregation. One of the early features of PD is disrupted mitochondrial dynamics, which arises from imbalances in cellular energy regulation. Therapeutic strategies that mitigate the mitochondrial dysfunction and enhance mitochondrial performance offer neuroprotection in PD. To delve into the role of mitochondrial function, we employed the synthetic PGC-1α activator ZLN005 to improve PD outcomes. In cellular PD model, we performed western blotting and immunofluorescence assays to assess disease-specific markers, including tyrosine hydroxylase and proteins related to mitochondrial biogenesis and regulation. Mitochondrial function was further evaluated using MitoTracker and ROS detection. We further investigated ZLN005 in a sub-acute MPTP mouse model. Motor performance was assessed, and subsequently, molecular analyses were conducted. Our findings revealed that ZLN005 significantly reduced MPP/MPTP-induced neurotoxicity, improved motor deficits, and maintained the expression of PGC-1α, tyrosine hydroxylase, and other key mitochondrial markers involved in DNA replication and mitophagy. Notably, proteins that enhance PGC-1α transcription, including SIRT1, were also upregulated. In addition, the expression of mitochondrial fusion proteins increased, a pattern supported by elevated levels of other transcriptional regulators. Imaging and flow cytometry further confirmed that PGC-1α activation improved mitochondrial integrity and reduced oxidative stress. These results provide preliminary insights into the potential therapeutic role of PGC-1α activator in PD. ZLN005 has a neuroprotective effect in PD, which is elaborated by PGC-1α activator regulating the mitochondrial quality control system. +

Full Text

Full text is available at the source.

View full text (PDF) ↗View full text (HTML) ↗View full text (PDF) ↗

Abstract

Full Text

Related papers